A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

Table 4 Adverse events

	Grade	Standard (N = 16)	Experimental (N = 14)	p value
Liver function abnormalities	G I/II	9 (56.3%)	9 (64.3%)	0.72
Liver function abnormalities	Grade III/IV	0 (0.0%)	2 (14.3%)	0.21
Fatigue	G I/II	8 (50.0%)	6 (42.9%)	0.73
Fatigue	Grade III/IV	0 (0.0%)	1 (7.1%)	0.47
Diarrhea	G I/II	7 (43.8%)	7 (50.0%)	1.00
Neuropathy	G I/II	3 (18.8%)	3 (21.4%)	1.00
Rash	G I/II	3 (18.8%)	3 (21.4%)	1.00
Hypokalemia	G I/II	5 (31.3%)	2 (14.3%)	0.40
Hypokalemia	Grade III/IV	1 (6.3%)	1 (7.1%)	1.00
Hypomagnesemia	G I/II	1 (6.3%)	0 (0.0%)	1.00
Mucositis	G I/II	1 (6.3%)	1 (7.1%)	1.00
Nail discoloration	G I/II	0 (0.0%)	1 (7.1%)	0.47
Skin discoloration	G I/II	0 (0.0%)	1 (7.1%)	0.47
Nausea	G I/II	3 (18.8%)	0 (0.0%)	0.23
Constipation	G I/II	0 (0.0%)	1 (7.1%)	0.47
Depression	G I/II	1 (6.3%)	1 (7.1%)	1.00
Anxiety	G I/II	1 (6.3%)	0 (0.0%)	1.00
Epistaxis	G I/II	0 (0.0%)	2 (14.3%)	0.21
Chest pain	G I/II	1 (6.3%)	0 (0.0%)	1.00
Myocardial infarction	G I/II	0 (0.0%	0 (0.0%)	1.00
Myocardial infarction	Grade III/IV/V	0 (0.0%)	1 (7.1%)	0.47
Musculoskeletal pain	G I/II	1 (6.3%)	0 (0.0%)	1.00
Breast pain	G I/II	1 (6.3%)	0 (0.0%)	1.00
Platelet count decreased	G I/II	0 (0.0%)	1 (7.1%)	0.47
Neutrophil count decreased	G I/II	0 (0.0%)	1 (7.1%)	0.47

ISSN: 1465-542X